

9 July 2026

To: Recipients of CLSI M100-Ed36

From: Jennifer K. Adams, MLS(ASCP), MSHA
Vice President, Standards and Quality

Subject: Correction

This notice is intended to inform users of corrections made to CLSI M100, *Performance Standards for Antimicrobial Susceptibility Testing*, 36th ed. The corrections are described below and shown as highlighted text in the table excerpt.

Table 2H-1. Zone Diameter and MIC Breakpoints for *Streptococcus* spp.β-Hemolytic Group:

The MIC breakpoints for the trimethoprim-sulfamethoxazole interpretive categories are missing the sulfamethoxazole concentrations. The interpretive categories have been corrected to read “≤ 0.5/9.5,” “1/19,” and “≥ 2/38.”

Table 2H-1. Zone Diameter and MIC Breakpoints for *Streptococcus* spp.β-Hemolytic Group

Antimicrobial Agent	Disk Content	Interpretive Categories and Zone Diameter Breakpoints, nearest whole mm			Interpretive Categories and MIC Breakpoints, µg/mL			Comments
		S	I	R	S	I	R	
		FOLATE PATHWAY ANTAGONISTS						
Trimethoprim-sulfamethoxazole	-	-	-	-	≤ 0.5/9.5	1/19	≥ 2/38	(14) Agar-based methods using MHA with 5% sheep blood (eg, disk diffusion, gradient diffusion, agar dilution) should not be performed due to increased thymidine content leading to false resistance. (15) Testing and reporting should be limited to isolates recovered from skin and skin structure infections; it is not indicated for isolates from other sources (eg, pharyngeal).

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service (customerservice@clsi.org).